#Canada #Montreal #Chief Medical Officer #CellCarta #Ehab A. El-Gabry

CellCarta Welcomes Dr. Ehab A. El-Gabry as Chief Medical Officer

CellCarta, a prominent global contract research organization (CRO) catering to the biopharmaceutical sector, is pleased to announce the appointment of Dr. Ehab A. El-Gabry as its new Chief Medical Officer (CMO) and Head of Companion Diagnostics (CDx). This strategic move is expected to significantly enhance the company’s capabilities in digital pathology and the application of artificial intelligence in diagnostics.

Dr. El-Gabry is taking the reins from Dr. Mark Kockx, the co-founder of CellCarta and its previous CMO, who is stepping down to prioritize personal health. Dr. Kockx’s leadership has been pivotal in shaping CellCarta into a trusted partner for customers worldwide, underpinned by his scientific acumen and dedication to customer relations.

In his new role, Dr. El-Gabry will oversee the medical and scientific direction of CellCarta’s biomarker programs and will spearhead the global pathology organization. His leadership aims to accelerate the development and commercialization of companion diagnostics by leveraging advancements in digital pathology and AI-based image analysis.

Dr. El-Gabry’s extensive experience spans over 25 years in clinical practice, diagnostic medicine, and translational research, particularly in oncology and precision diagnostics. His past roles include serving as Head of CDx Pathology at Roche Tissue Diagnostics and Chief Medical Officer at Akoya Biosciences, among others. He is particularly recognized for his contributions to FDA-approved companion diagnostics, including the PD-L1 assay, and his accomplishments in promoting digital pathology and AI applications.

As CellCarta continues to grow its dedicated pathology network, the focus will also include strengthening histopathology and genomics connections to ensure a seamless integration from biomarker strategy through to clinical trials and regulatory validation. A significant part of Dr. El-Gabry’s strategy will revolve around expanding digital pathology workflows and AI algorithm validation, aiming for an objective and reproducible assessment of tissue biomarkers. This approach not only enhances efficiency but also ensures scalability across diverse clinical settings globally.

CellCarta’s commitment to maintaining quality and consistency in its services is further reinforced by its international presence, which spans critical markets including China. This expansive reach enables the company to offer standardized scoring, interpretation, and quality assurance vital for sponsors executing global trial strategies.

CellCarta’s Chief Executive Officer, Dusty Tenney, expressed enthusiasm about Dr. El-Gabry’s arrival, underscoring how his proven experience in leading FDA-approved diagnostics and digital pathology initiatives will greatly benefit their customer base. Tenney also took a moment to acknowledge Dr. Kockx’s invaluable contributions to the company, recognizing his foundational impact and the trust he cultivated within the industry.

In embracing his new responsibilities, Dr. El-Gabry stated, "CellCarta has established a robust framework in histopathology and genomics, supported by thorough scientific knowledge and operational efficiency. I look forward to leading the pathology division and evolving CellCarta’s CDx strategy by incorporating digital pathology and AI solutions into our workflows. This integration is essential for delivering the precision and scalability needed for global CDx development and commercialization, ensuring optimal therapeutic outcomes for patients."

For more information about CellCarta’s initiatives in companion diagnostics and its capabilities in digital pathology, visit CellCarta.com.

About CellCarta

CellCarta stands out as a leading global CRO within the biopharmaceutical industry, holding CAP accreditations and CLIA certifications for specific testing methodologies. The organization operates facilities across Canada, the USA, Belgium, Australia, and China, providing a broad spectrum of biomarker testing and custom solutions for top-tier pharmaceutical companies. By harmonizing analytical platforms in immunology, histopathology, proteomics, and genomics with rigorous sample management and logistical services, CellCarta supports every stage of the drug development process, from initial discovery to late-stage clinical trials.